Schug Lab retweeted
NEW: Today, I’m releasing a Surgeon General’s Advisory on the causal link between alcohol consumption and increased cancer risk. Alcohol is the 3rd leading preventable cause of cancer in the U.S., contributing to about 100,000 cancer cases and 20,000 cancer deaths each year.
Schug Lab retweeted
Happy to announce our collaboration with @Tcellogic on metabolic features of exhausted T cells is now out in @ScienceMagazine. TL;DR they can't use acetate to fuel their function. Great work by Shixin Ma and Mike Dahabieh. science.org/doi/10.1126/scie…
Schug Lab retweeted
Our work on metabolism of quiescent cells! A bit of a new area for us in collaboration with the Buckanovich lab
New research reveals that #acetate drives quiescence in ovarian #cancercells by boosting ACSS2-mediated acetyl-CoA production. High ACSS2 levels are linked to poor patient outcomes and #chemoresistance.
Targeting ACSS2 could enhance treatment response!
🔗sciencedirect.com/science/ar…
Schug Lab retweeted
Thanks to support from @TheVFoundation, @NanZhangWistar and @AuslanderNoam have been named as V Scholars and awarded $1.2 million in grant funding to support research that aims to improve existing cancer therapies. Our story: bit.ly/4gudEpE
Schug Lab retweeted
My baby girl came on Monday night and closing the week with a first author paper from @DrRGJonesLab ! What a week!! Many thanks to everyone for all the efforts to get this paper out!!
Kaymak, Watson @DrRGJonesLab @VAInstitute and colleagues show that production of cytosolic acetyl-CoA by ACLY and ACSS2 links CD8 T cell metabolic state and effector function through effects on #chromatin accessibility. hubs.la/Q02Lzc7r0
#Metabolism #LymphocyteBiology
Schug Lab retweeted
No amount of alcohol is safe but the risk of limited consumption is limited but dictated by underlying conditions. This is an excellent summary of meta-analyses @nytimes nytimes.com/2024/06/15/magaz…
Schug Lab retweeted
New preprint from the lab is online! The product of a stellar collaboration with @Muir_Lab, we explore a chemically defined physiologic media formulation based of the metabolite of tumor interstitial fluid (TIF, or “tumor juice”) and its effects on T cell function! A brief 🧵1/
Schug Lab retweeted
Meet Nathaniel W. Snyder @mzspectrum Winner of the 2024 Chemical Research in Toxicology Young Investigator Award! Read our interview here 🔗 go.acs.org/9HM
Schug Lab retweeted
Happy to report that our paper, where we grapple with the mystery of ACLY splice isoforms, is finally out!
jbc.org/article/S0021-9258(2…
@WellenLab @MarmorsteinLab
Schug Lab retweeted
🔬 Excited to share @SchugLab’s latest findings at #ASMS2024! Join me at the poster session where we’ll delve into:
1. Targeted Metabolomics.
2. FASN (Fatty Acid Synthase) and fatty acid biosynthesis.
3. Coenzymes A, malonate, and succinate.
4. Mitochondria (should I add ‘powerhouses’?).
➡️ ThP133, Thu, June 6, 10:30 am ⬅️
See you there! 🌟🧪📊
#TeamMassSpec
Schug Lab retweeted
Happy to share our new paper in print today in @ScienceAdvances exploring nutrient utilization by CD8 T effector cells in vivo using infusion of 13C tracers. Great work by Eric Ma, Mike Dahabieh and collaborators at @VAInstitute and @AgiosPharma. science.org/doi/10.1126/scia…
Schug Lab retweeted
I am excited to share our preprint "Identification of Fasnall as a therapeutically effective Complex I inhibitor."
biorxiv.org/content/10.1101/…
Several things from inside 👇
We asked a question: What happens with the polar metabolome of cancer cells when fatty acid synthase (FASN) is inhibited?
We found that three widely used FASN inhibitors likely do not inhibit FASN in cells.
Instead, we reassign one of them, Fasnall, as a new Complex I inhibitor. Fasnall can reach therapeutic concentrations in vivo and effectively prevent tumor growth in several OXPHOS-dependent tumor models (breast cancer xenografts and one model of BRAFi/MEKi double-resistant melanoma PDX).
Fasnall joins the set of known Complex I inhibitors, such as rotenone, metformin, mubritinib, and IACS-010759. Unlike the latter, Fasnall seemingly does not cause painful neuropathies in vivo. Mubritinib (TAK-165) was previously known as an ERBB2 inhibitor, and its activity was reassessed in the work by Baccelli et al. (2019). 🧵
Schug Lab retweeted
We are proud of the work one of our grantees, @SchugLab, is doing @TheWistar for breast cancer research. They've proven that the immune system can help kick Triple Negative Breast Cancer out! While still early, Our CSO, Dr. @susannagreer, puts it into perspective!
Schug Lab retweeted
ONLINE NOW @NatureCancer “Acetate acts as a metabolic immunomodulator by bolstering T-cell effector function and potentiating antitumor immunity in breast cancer” by #ZacharySchug & Co.
nature.com/articles/s43018-0…
rdcu.be/dndEL
Schug Lab retweeted
1/ Excited to see this article published @NatureCancer. In a brilliant collaboration with Jürgen Ruland, Tim Wartewig, @Jay___Daniels, and Miriam Schulz discovered the mechanisms by which PD1 constrains T cell lymphomagenesis.
nature.com/articles/s43018-0…
Schug Lab retweeted
We’re very excited to share the latest findings of @cancergrand Team Rosetta, out in @NatMetabolism now!!! nature.com/articles/s42255-0…
Schug Lab retweeted
C/EBPa Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stress-induced #Ferroptosis in FLT3-mutant #Leukemia— by @MarieSabatier_, Birsen, @LauraLauture, Mouche, Tamburini, @jeansarry et al.
bit.ly/3nRCg5U
@unige_en @crctoncopole
Schug Lab retweeted
“Her diagnosis had a lasting impact on my research. It made me a better researcher. For me, it’s not just a job,” says vice president of Research Dr. Eyal Gottlieb of his wife’s brain tumor diagnosis. His vision for MD Anderson: fal.cn/3x3VC @GottliebLab #EndCancer
Schug Lab retweeted
Targeting the mevalonate pathway suppresses ARID1A-inactivated cancers by promoting pyroptosis cell.com/cancer-cell/fulltex…
Schug Lab retweeted
🆕 Paper from @Joharrr @owen_sansom & colleagues where they use mass-spectrometry based metabolomics to investigate the metabolic impact of colorectal cancer driver mutations.
biorxiv.org/content/10.1101/…




























